Showing 411 - 420 of 1,415
Background: Value-based pricing (VBP), whereby prices are set according to the perceived benefits offered to the consumer at a time when costs and benefits are characterized by considerable uncertainty and are then reviewed ex post, is a much discussed topic in pharmaceutical reimbursement. It...
Persistent link: https://www.econbiz.de/10008690230
Background: Knee cartilage lesions increase the risk of developing osteoarthritis (OA), and may eventually result in a total knee replacement (TKR). There is currently no consensus on the optimal treatment of cartilage lesions. ChondroCelect (CC) is a cell-based therapy approved for use in...
Persistent link: https://www.econbiz.de/10008725815
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of cetuximab (Merck Serono) to submit evidence for the clinical and cost effectiveness of cetuximab in combination with platinum-based chemotherapy (CTX) for the treatment of patients with recurrent and/or...
Persistent link: https://www.econbiz.de/10008467350
Background: The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This...
Persistent link: https://www.econbiz.de/10008467351
Background: Although 5-alpha reductase inhibitors (5ARIs) have demonstrated that they reduce the risk of prostate cancer (PCa), they have not demonstrated cost effectiveness in the patient populations in which they have been examined. Objective: A decision-analytic model was created to explore...
Persistent link: https://www.econbiz.de/10008467353
Background: Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. Objective: To...
Persistent link: https://www.econbiz.de/10008462721
Background: Several treatment options are available for patients with type 2 diabetes mellitus who are making the transition from oral antidiabetes drugs (OADs) to insulin. Two options currently recommended by the Canadian Diabetes Association for initiating insulin therapy in patients with type...
Persistent link: https://www.econbiz.de/10008462723
Persistent link: https://www.econbiz.de/10010376453
Persistent link: https://www.econbiz.de/10011947472
Persistent link: https://www.econbiz.de/10011719924